|
Name |
Sclerotiamide
|
Molecular Formula | C26H29N3O5 | |
IUPAC Name* |
(1'R,3R,7'S,9'S,12'S)-12'-hydroxy-7,7,10',10'-tetramethylspiro[1H-pyrano[2,3-g]indole-3,11'-3,13-diazatetracyclo[5.5.2.01,9.03,7]tetradecane]-2,2',14'-trione
|
|
SMILES |
CC1(C=CC2=C(O1)C=CC3=C2NC(=O)[C@@]34[C@@H]([C@]56[C@H](C4(C)C)C[C@@]7(CCCN7C5=O)C(=O)N6)O)C
|
|
InChI |
InChI=1S/C26H29N3O5/c1-22(2)10-8-13-15(34-22)7-6-14-17(13)27-20(32)25(14)18(30)26-16(23(25,3)4)12-24(19(31)28-26)9-5-11-29(24)21(26)33/h6-8,10,16,18,30H,5,9,11-12H2,1-4H3,(H,27,32)(H,28,31)/t16-,18-,24-,25-,26+/m0/s1
|
|
InChIKey |
CFJMAERFDLWMJL-LQKPOZSPSA-N
|
|
Synonyms |
Sclerotiamide; (-)-Sclerotiamide; CHEMBL511731; BDBM50535809; (1'R,3R,7'S,9'S,12'S)-12'-hydroxy-7,7,10',10'-tetramethylspiro[1H-pyrano[2,3-g]indole-3,11'-3,13-diazatetracyclo[5.5.2.01,9.03,7]tetradecane]-2,2',14'-trione
|
|
CAS | NA | |
PubChem CID | 10647785 | |
ChEMBL ID | CHEMBL511731 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 463.5 | ALogp: | 1.1 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 108.0 | Aromatic Rings: | 8 |
Heavy Atoms: | 34 | QED Weighted: | 0.547 |
Caco-2 Permeability: | -5.247 | MDCK Permeability: | 0.00002620 |
Pgp-inhibitor: | 0.985 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.109 | 20% Bioavailability (F20%): | 0.905 |
30% Bioavailability (F30%): | 0.887 |
Blood-Brain-Barrier Penetration (BBB): | 0.558 | Plasma Protein Binding (PPB): | 80.36% |
Volume Distribution (VD): | 0.908 | Fu: | 17.46% |
CYP1A2-inhibitor: | 0.01 | CYP1A2-substrate: | 0.326 |
CYP2C19-inhibitor: | 0.078 | CYP2C19-substrate: | 0.884 |
CYP2C9-inhibitor: | 0.387 | CYP2C9-substrate: | 0.097 |
CYP2D6-inhibitor: | 0.042 | CYP2D6-substrate: | 0.128 |
CYP3A4-inhibitor: | 0.876 | CYP3A4-substrate: | 0.904 |
Clearance (CL): | 5.718 | Half-life (T1/2): | 0.31 |
hERG Blockers: | 0.012 | Human Hepatotoxicity (H-HT): | 0.831 |
Drug-inuced Liver Injury (DILI): | 0.882 | AMES Toxicity: | 0.54 |
Rat Oral Acute Toxicity: | 0.992 | Maximum Recommended Daily Dose: | 0.969 |
Skin Sensitization: | 0.324 | Carcinogencity: | 0.963 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.005 |
Respiratory Toxicity: | 0.883 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004071 | 0.854 | D02JNM | 0.222 | ||||
ENC004946 | 0.815 | D0P0HT | 0.221 | ||||
ENC002538 | 0.792 | D00ETS | 0.217 | ||||
ENC002534 | 0.738 | D02QJH | 0.216 | ||||
ENC002366 | 0.738 | D06XZW | 0.216 | ||||
ENC002536 | 0.738 | D03ZZK | 0.213 | ||||
ENC004072 | 0.690 | D06YFA | 0.210 | ||||
ENC004948 | 0.646 | D0W7RJ | 0.210 | ||||
ENC002704 | 0.646 | D0D2TN | 0.210 | ||||
ENC004944 | 0.622 | D0C7JF | 0.209 |